Plus Therapeutics secures Humana coverage for brain cancer test

Plus Therapeutics Inc. (NASDAQ: PSTV) announced that its subsidiary CNSide Diagnostics has signed a national coverage agreement with Humana Inc. (NYSE: HUM) for the CNSide cerebrospinal fluid assay. The agreement, effective October 29, covers approximately 16 million people across the United States.

The coverage agreement brings total policy coverage for the CNSide CSF tumor cell enumeration laboratory developed test to 67 million people. The test is designed to detect tumor cells in cerebrospinal fluid for patients with leptomeningeal metastases, a condition where cancer spreads to the membranes surrounding the brain and spinal cord.

According to the company, more than 11,000 CNSide tests have been performed at over 120 U.S. cancer institutions since 2020. The test demonstrates 92% sensitivity and 95% specificity, with the company stating it influences treatment decisions in 90% of cases.

The CNSide CSF assay platform supports diagnosis, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The test is available exclusively through CNSide Diagnostics as a testing service for healthcare professionals in the United States.

CNSide Diagnostics is a wholly-owned subsidiary of Plus Therapeutics, which develops targeted radiotherapeutics for central nervous system cancers. The Houston-based clinical-stage pharmaceutical company focuses on treatments for leptomeningeal metastases and recurrent glioblastoma.

You May Also Be Interested In